Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

JenaValve Technology, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

JenaValve Technology, Inc.

Regulatory records
3
Linked recall entries
3
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 3 FDA records to the applicant name JenaValve Technology, Inc.. It includes 1 original PMA approval. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Mar 17, 2026 to Oct 13, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NPT appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250024, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 4 Cromwell, Irvine, CA, 92618. Recorded on P250024/S005, decision dated Oct 13, 2026.

Changes described in PMA records

P250024/S005: Trilogy Transcatheter Heart Valve System

The FDA record for P250024/S005, dated 2026-10-13, is a 30-Day Notice under the Trilogy Transcatheter Heart Valve System PMA, filed by JenaValve Technology, Inc. The supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the stated change is "an additional abattoir for sourcing pericardium tissue." The device category is a percutaneously delivered aortic valve prosthesis (product code NPT).

Because the record names P250024, this submission modifies the existing PMA rather than granting approval of the whole system; the decision is logged as OK30, and the notice concerns a supplier arrangement for pericardium tissue sourcing. The supplied fields do not identify the abattoir, its location, tissue acceptance criteria, or any verification data tied to the added source. The stated purpose of the notice is not evidence of safety or clinical effectiveness.

FDA approval-order wording

an additional abattoir for sourcing pericardium tissue

Oct 13, 2026 · 30-Day Notice

P250024/S006: Trilogy Transcatheter Heart Valve System

The supplied record describes PMA supplement P250024/S006 for the Trilogy Transcatheter Heart Valve System, applicant JenaValve Technology, Inc., with a decision dated 2026-10-07 and a designation shown as OK30. The supplement is a 30-Day Notice under the reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier," and the statement gives its scope as "an alternate supplier for delivery catheter components." The device category is an aortic valve prosthesis delivered percutaneously, product code NPT, specialty Cardiovascular.

The identifier links this supplement to original PMA P250024, so the action amends manufacturing arrangements within that approved filing rather than constituting approval of the whole system. The statement does not identify the alternate supplier, the specific components affected, the prior supplier, or the date any change takes effect; it also does not report safety or clinical effectiveness findings, and the OK30 designation is not explained in the supplied fields.

FDA approval-order wording

an alternate supplier for delivery catheter components

Oct 7, 2026 · 30-Day Notice

P250024: Trilogy Transcatheter Heart Valve System

The FDA approved the Trilogy Transcatheter Heart Valve System from JenaValve Technology, Inc. for treating symptomatic, severe native tricuspid aortic valve regurgitation. The approval excludes cases caused by acute endocarditis, rheumatic heart disease, or acute aortic dissection.

Eligibility requires a Heart Team, including a cardiac surgeon, to judge the patient at high or greater risk for surgical aortic valve replacement. That judgment uses a predicted 30-day surgical mortality of 8% or higher based on the Society of Thoracic Surgeons risk score and other clinical co-morbidities not measured by the STS risk calculator.

FDA approval-order wording

The Trilogy Transcatheter Heart Valve System is indicated for the treatment of symptomatic, severe native tricuspid aortic valve regurgitation (not due to acute endocarditis, rheumatic heart disease, or acute aortic dissection) in patients who are judged by a Heart Team, including a cardiac surgeon, to be at high or greater risk for surgical aortic valve replacement (i.e., predicted risk of surgical mortality >=8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Mar 17, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 3 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 3 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 19, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
JenaValve Technology, Inc.PMA supplementOct 13, 2026FDA
JenaValve Technology, Inc.PMA supplementOct 7, 2026FDA
JenaValve Technology, Inc.PMA approvalMar 17, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.